This site is intended for healthcare professionals
News

CHMP recommends Nepexto a etanercept biosimilar.- Mylan

Read time: 1 mins
Published:1st Apr 2020
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Nepexto, intended for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis (ankylosing spondylitis, non-radiographic axial spondyloarthritis), plaque psoriasis and paediatric plaque psoriasis. Nepexto will be available as 25 mg and 50 mg solutions for injection. The active substance of Nepexto is etanercept, an immunosuppressant (ATC code: L04AB01). Etanercept is a fusion protein, which preferentially binds to tumour necrosis factor alpha (TNF-alpha) and thereby inhibits its biological activity. Nepexto is a biosimilar medicinal product from Mylan. It is highly similar to the reference product Enbrel (etanercept), which was authorised in the EU on 3 February 2000. Data show that Nepexto has comparable quality, safety and efficacy to Enbrel.
Condition: Rheumatoid Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.